BEIJING, SHANGHAI, China, January 7, 2019—CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, and GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), announced an exclusive licensing agreement in the greater China area to commercialize Hunterase™, a human recombinant iduronate-2-sulfatase (IDS) enzyme replacement therapy for the treatment of Hunter syndrome. Developed by GC Pharma, Hunterase is marketed in more than ten countries worldwide. There is no approved treatment for Hunter syndrome in China, unlike in some parts of the world.
“Hunterase is the first rare disease drug CANbridge will commercialize in China,” said James Xue, Ph.D., Founder, Chairman and CEO, CANbridge Pharmaceuticals Inc. “Our corporate mission is to develop and commercialize treatments for rare diseases in China. We are encouraged that recent regulatory reforms in China could provide patients with access to these much-needed therapies more quickly. Like so many rare diseases, there is no treatment for Hunter syndrome in China, short of palliative care. We look forward to the possibility of bringing this important treatment option to Hunter syndrome patients and their families.”
“We are delighted to further enhance the value of Hunterase through this partnership,” said Eun Chul Huh, Ph.D., President GC Pharma. “Our ultimate goal is to make a meaningful difference in the lives of those with Hunter syndrome in all markets. With an established team in China, CANbridge is the ideal partner to reach this important and large market.”
About Hunter syndrome
Hunter syndrome (Mucopolysaccharidosis type II) is an inherited lysosomal storage disease that occurs primarily in boys. It causes an enzyme deficiency that interferes with the body’s ability to break down certain complex sugars, resulting in serious skeletal, tissue, neurological and multi-organ complications and, ultimately, death. It occurs in approximately 1.3 out of 100,000 male newborns. There is no cure. The standard treatments are enzyme replacement therapy (ERT) or palliative care. Mucopolysaccharidosis is one of the 121 diseases on the China Rare Disease List recently published by the Chinese government.
About GC Pharma
GC Pharma is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, GC Pharma is one of the largest protein products manufacturers in the world and has been dedicated to quality healthcare solutions more than half a century. Green Cross Corporation updates its corporate brand as GC Pharma in early 2018. Green Cross Corporation remains the company's registered, legal name.
About CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a China-based biopharmaceutical company accelerating development and commercialization of specialty healthcare products for orphan diseases and targeted cancers, focusing on products that are unavailable or address medical needs that are underserved in the region.
CANbridge has been widely recognized as a leader in orphan diseases in China, and has a partnership with WuXi Biologics to develop and commercialize proprietary therapeutics for the treatment of rare diseases. CANbridge also has exclusive rights to develop and commercialize Puma Biotechnology’s NERLYNX® (neratinib) in China, Taiwan, Hong Kong and Macao (collectively, greater China); a license with Apogenix to develop and commercialize APG101 in greater China; a license (ex-North America) to develop and commercialize AVEO Oncology’s ErbB3 (HER3) inhibitory antibody candidate AV203 and an agreement with EUSA Pharma to commercialize Caphosol® for the prevention and treatment of oral mucositis caused by cancer treatments, for which it has received approval in China.
For more on CANbridge Pharmaceuticals Inc., please go to www.canbridgepharma.com.
CANbridge Pharmaceuticals Inc.
Media (GC Pharma):
Hyun Goo Kang
Manager, Public Relations
GC(Green Cross Holdings)